NCT02242097View on ClinicalTrials.gov

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 12, 2015

Primary Completion Date

January 5, 2023

Study Completion Date

January 31, 2025

Conditions
Contiguous Stage II Mantle Cell LymphomaNoncontiguous Stage II Mantle Cell LymphomaStage I Mantle Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell Lymphoma
Interventions
DRUG

ibrutinib

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (5)

44195

Cleveland Clinic, Cleveland

60045

Northwestern University- Lake Forest Hospital, Lake Forest

60611

Northwestern University, Chicago

84132

University of Utah, Salt Lake City

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER